Request Demo
Affibody regains autoimmune asset, claims ex-partner Acelyrin unable \'to fully capitalize\' on potential
Phase 3Clinical ResultDrug ApprovalIPOAcquisition
Once the termination is effective, Affibody will regain all rights to the candidate.
Acelyrin has punted the autoimmune Affibodyspect izokibep back to Affibody, completing a retreat from its former lead candidate that began with the axing of development in two diseases in August. The news led Affibody to claim its former partner “has not been able to fully capitalize” on the asset’s potential.
California-based Acelyrin licensed izokibep in 20izokibep25 millioAffibodyt. The biotech, which agreed to pay up to $280 million in milestones, had no significant operations before striking the deal for the ILAffibodyibitor. Less than two years later, Acelyrin raised $540 million in an IPO to bankroll late-phase trials of izokibep in multiple indications.
“We are convinced that izokibep, wiizokibeplear path to approval and competitive profile, can become a game-changing drug in theAffibodylogy field, particularly for the significant number of patients debilitated by [hidradenitis suppurativa],” Bejker said in a statement. “It is clear that Acelyrin has not been able to fully capitalize on the potential demonstrated by izokibep’s best-in-class phase 3 data.”
A phase 3 trial of izokizokibephidradenitis suppurativa, a skin condition characterized by abscesses, met its primary endpoint last year. Acelyrin found 33% of patients who took izokibep had a 75% or greater reductiohidradenitis suppurativammatory nodules, compared to 21% of people on placebo. Yet, having hit the primary and secondary endpoints, Acelyrin simultaneouslizokibepd investing in the indication.
At the same time, tizokibepch phidradenitis suppurativac arthritis—a disease in which it scabscessesase 2b/3 win earlier in 2024—to leave uveitis as its last remaining area of acizokibepkibep development. The phase 2b/3 uabscessesial missed its primary and secondary endpoints late last year.
With Inmagene Biopharmaceuticals recently endinpsoriatic arthritissian countries including China and South Korea, responsibility for izokiuveitisl fall squarely on Sweden’s Affibody. izokibep CEO Mina Kim has framed gettuveitiskibep to market in hidradenitis suppurativa as a job for a big company with an existing footprint in the indication. Izokibep failed an earlier trial in the indication in 2023.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!